Product Overview

AOP Orphan's focus is on Rare Diseases. The portfolio comprises products in the following therapeutic areas: HematoOncology, Cardiology & Pulmonology, Neurology and Metabolic Disorders. AOP Orphan’s strategic goal is to constantly deliver new treatment options with respect to Rare Diseases.

HematoOncology

BESREMi®

BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia Vera without symptomatic splenomegaly.

Drug Facts
Active Ingredient
Ropeginterferon alfa-2b
HematoOncology

Busilvex®

Busilvex® is a concentrate used to conditioning treatment prior to stem cell transplantation. Pierre Fabre is the MA-Holder and AOP Orphan has the distribution right.

Drug Facts
Active Ingredient
Busulfan
HematoOncology

Thromboreductin®

Thromboreductin® is indicated for the reduction of elevated platelet counts and associated clinical symptoms in at high risk essential thrombocythemia patients

Drug Facts
Active Ingredient
Anagrelide